bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
168 hedge funds and large institutions have $273M invested in bluebird bio in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 53 increasing their positions, 46 reducing their positions, and 22 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 46
0.21% less ownership
Funds ownership: 4.41% → 4.19% (-0.21%)
4% less funds holding
Funds holding: 175 → 168 (-7)
12% less capital invested
Capital invested by funds: $309M → $273M (-$35.8M)
20% less call options, than puts
Call options by funds: $4.45M | Put options by funds: $5.56M
27% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 22
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$7.21M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$6.83M |
| 3 |
CIM
Contrarius Investment Management
St. Helier,
Jersey
|
+$4.59M |
| 4 |
BL
Bleichroeder LP
New York
|
+$3.16M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$2.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$13M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$10.9M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$4.37M |
| 4 |
Walleye Capital
New York
|
-$2.75M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$2.52M |
BLUE Hedge Fund Activity: Q3 2023 in Review
168 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q3 2023, worth a combined $273M — down 12% from $309M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of BLUE and 16 opened new positions — a net loss of 6 holders — while 46 trimmed existing stakes and 53 added.
The largest buyer was Ameriprise, adding an estimated $7.21M. The largest seller was State Street, cutting an estimated $13M.
- 168 institutional investors held bluebird bio (BLUE) as of Q3 2023, down from 175 in Q2 2023.
- Funds reported $273M of bluebird bio stock for Q3 2023, down 12% quarter-over-quarter.
- 16 funds opened new bluebird bio positions in Q3 2023 and 22 closed out, a net change of -6 holders.
- The largest bluebird bio buyer in Q3 2023 was Ameriprise, an estimated $7.21M added.
- The largest bluebird bio seller in Q3 2023 was State Street, an estimated $13M sold.
Based on aggregated 13F filings for Q3 2023.